Sanofi, AstraZeneca and two leading trade groups want clarity around an appellate decision that called for Teva to delist ...

A legal challenge by Amgen against Sanofi and Regeneron could be so successful it could end in its rivals' PCKS9 drug Praluent forced off the market. Amgen has just won its patent case in the ...

Last year, Yeda Research and Development, the tech transfer office of the Weizmann Institute, sued ImClone and Sanofi-Aventis over the Erbitux patent. (The patent was owned by the latter and licensed ...

Glaxo’s patent for Zantac’s active ingredient ... with the exception of Delaware where the majority of the cases are pending.